Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Sep;13 Suppl 3(Suppl 3):47-51.
doi: 10.1111/iwj.12632.

Epidermal skin grafting in vitiligo: a pilot study

Affiliations
Case Reports

Epidermal skin grafting in vitiligo: a pilot study

Agata Janowska et al. Int Wound J. 2016 Sep.

Abstract

Vitiligo is a multifactorial acquired dermatosis characterised by achromic or hypochromic macules and by the absence of functioning melanocytes. Treatment depends on the extent of the affected areas and on disease activity. Surgical techniques have proven to be effective in stable cases but can be time-consuming and, in some cases, aesthetically unsatisfying or painful for the patients. The aim of the study was to assess the clinical safety and effectiveness of a new automatic epidermal skin harvesting device in patients with stable localised vitiligo over a minimum 12-month period. This new system (CELLUTOME™ Epidermal Harvesting System, KCI, an ACELITY Company, San Antonio, TX) is a commercially available epidermal skin harvesting system that can be used without local anaesthesia or other pre-treatments and has been shown to have low rates of donor site morbidity. Epidermal skin grafts can used in patients with acute and hard to heal chronic wounds, burns and stable vitiligo. The use of advanced therapies may improve the quality of life, have cost benefits and accelerate re-pigmentation of patients with vitiligo. In our preliminary study, this system was seen to be a safe and efficacious means of harvesting epidermal micrografts containing melanocytes for use in patients with stable vitiligo unresponsive to standard therapies.

Keywords: Epidermal skin grafting; Skin grafting; Vitiligo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Curettage of recipient site.
Figure 2
Figure 2
Representative photo depicting epidermal micrograft engraftments 7–14 days post epidermal grafting. The whole graft recipient site (A) and a 10× magnification of the micrograft (HEINE Delta® 20T Dermatoscope, HEINE Optotechnik, Herrsching, Deutschland) (B) are shown.
Figure 3
Figure 3
Photo showing 100% repigmentation following epidermal skin grafting. The patient's hand prior to epidermal grafting (A) and 1 month after epidermal grafting (B) are shown.
Figure 4
Figure 4
Representative photo of 50–75% repigmentation. Vitiligo area prior to epidermal grafting (A) and 2 months after epidermal grafting (B) are shown.

Similar articles

Cited by

References

    1. Lee H, Lee MH, Lee DY, Kang HY, Kim KH, Choi GS, Shin J, Lee HJ, Kim DH, Kim TH, Lee AY, Lee SC, Lee S, Kim KW, Hann SK, Park CJ, Oh SH. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J 2015;56:719–25. - PMC - PubMed
    1. Meurer M, Schild M. Treatment of vitiligo. Hautarzt 2016;67:249–64. - PubMed
    1. Machado Filho CD, Timoner FR. Epidermal curettage technique (ECT) for tissue harvest from the donor area for melanocyte autologous grafting in cases of vitiligo. An Bras Dermatol 2014;89:681–3. - PMC - PubMed
    1. Boschi E, Longoni BM, Romanelli M, Mosca F. Cutaneous tissue engineering and lower extremity wounds (part 1). Int J Low Extrem Wounds 2004;3:80–6. - PubMed
    1. Cervelli V, Spallone D, Lucarini L, Palla L, Brinci L, De Angelis B. Treatment of stable vitiligo hands by ReCell system: a preliminary report. Eur Rev Med Pharmacol Sci 2010;14:691–4. - PubMed

Publication types

LinkOut - more resources